World Health Organization Raises Warning Over Critical Scarcity of Obesity Jabs

Under 10% of people that would benefit from obesity jabs such as Wegovy can access them, states the WHO as it publishes its first advice on the therapies.

Considering in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is advocating for broader and more equitable availability to this class of drugs.

According to estimates, in excess of 2,000,000,000 will be living with obesity by 2030 unless action is taken.

"The new guidelines recognises that excess weight is a long-term condition that can be managed with comprehensive and continuous care," stated WHO director-general Tedros Adhanom Ghebreyesus.

Substantial prices, insufficient output, and supply-chain constraints are key hurdles to universal availability to the injections that can assist patients in reducing significant body mass, says the body.

Skinny Jab Supply Crisis

Even under the present most optimistic case, the production of these medications might only reach approximately 100 million people – less than 10% of eligible patients, according to the WHO.

The guideline encourages nations and manufacturers to widen access, through measures such as patent sharing.

Exclusive production rights on the active ingredient – the primary ingredient of the drug Wegovy – is scheduled to end in several nations in 2026.

How Obesity Drugs Work

The injections mimick a natural hormone to reduce digestion speed, reduce hunger and enhance satiety so individuals reduce food intake.

Individuals typically begin shedding pounds after several weeks of commencing the once-weekly jabs.

Research indicates people may see weight return a year later of discontinuing the drug, because their usual appetite return.

Being overweight or obese elevates your likelihood for developing diseases, such as type 2 diabetes, cardiovascular issues, stroke, and certain cancers.

Excess weight concerns people in every country and was linked to over three and a half million deaths worldwide in 2024, per the health agency.